Current diagnostic techniques for MiTF RCC heavily rely on fluorescent in situ hybridization (FISH) assays. This method employs fluorescent probes targeted to specific DNA sequences, particularly focusing on TFE3 and TFEB gene rearrangements known to drive oncogenesis in this cancer subtype. FISH testing serves as the gold standard in clinical settings, affording pathologists a direct visualization of chromosomal abnormalities within tumor cells. While FISH is invaluable for confirming MiTF RCC, it is not without limitations; false-negative results can arise due to cryptic or complex rearrangements that evade detection, potentially leading to underdiagnosis and missed opportunities for tailored therapies.

Rohit Mehra, M.D., the Godfrey Dorr Stobbe Research Professor of Translational Pathology, spearheaded the investigation after observing an intriguing pattern. Some renal cell carcinoma tumors that tested negative by FISH assays nonetheless exhibited morphological characteristics strongly suggestive of MiTF RCC. This paradox prompted a deeper inquiry into the alternative biomarkers and genetic expressions that might better capture the heterogeneity of these tumors. Collaborating with the Michigan Center for Translational Pathology, Dr. Mehra’s team turned their focus to TRIM63, a gene previously associated with MiTF family altered RCC but not systematically investigated in FISH-negative cases.

Their research revealed a compelling link: tumors that were FISH negative yet overexpressed TRIM63 frequently harbored MiTF-associated genetic alterations undetected by conventional assays. TRIM63, known to function in protein ubiquitination and degradation pathways, may serve as a sensitive biomarker for identifying elusive gene rearrangements underpinning tumorigenesis. By deploying advanced genomic techniques alongside immunohistochemical analysis, the team uncovered that approximately 70% of these TRIM63-positive but FISH-negative cases indeed possessed MiTF gene fusions, underscoring the diagnostic blind spots of relying solely on FISH.

This finding has considerable clinical significance. The realization that TRIM63 immunohistochemistry can complement FISH assays introduces a new diagnostic paradigm, enhancing precision in classifying renal tumors with ambiguous genetic profiles. Identifying MiTF alterations is critical, as these tumors often display aggressive behavior and may benefit from targeted therapies or enrollment in clinical trials tailored to their molecular drivers. Expanding the diagnostic toolkit to include TRIM63 assessment could, therefore, unlock a subset of patients previously deemed ineligible for such interventions based on incomplete genetic information.

The methodological rigor of the study, published in the esteemed journal Modern Pathology, entailed comprehensive genomic analyses, including next-generation sequencing and RNA profiling, to validate TRIM63’s role as a diagnostic marker. This integrative approach strengthens the evidence base and ensures that the conclusions drawn are grounded in multi-layered molecular data. The research also demonstrated that the overexpression of TRIM63 is not merely correlative but likely reflective of underlying genomic aberrations affecting the MiTF transcriptional network.

Moreover, the study builds upon prior pioneering efforts by Jeffrey Myers, M.D., and Arul Chinnaiyan, M.D., Ph.D., who conceptualized complex genitourinary esoteric clinical assays to unravel molecular intricacies of urologic cancers. Their foundational work paved the way for such nuanced investigations that blend morphology, immunohistochemistry, and genomic science to redefine diagnostic boundaries. The University of Michigan’s multidisciplinary collaboration exemplifies how translational pathology bridges basic research and clinical application, ultimately improving patient outcomes.

The implications of these findings extend beyond immediate diagnostic refinement. They suggest a broader need to reconsider reliance on traditional assays that may miss cryptic genetic changes in heterogeneous tumors. This study underscores the evolving landscape of precision medicine, where molecular profiling increasingly informs treatment decisions. As clinical oncology moves toward individualized therapeutic strategies, the capacity to accurately define tumor biology at the genetic level becomes paramount.

Given that TRIM63 has been integrated into clinical biomarker panels at U-M for over two years, this study’s results validate and encourage wider adoption of such testing in other institutions. The prospect of reducing false negatives in MiTF RCC diagnosis is a significant stride toward better patient stratification and management. Future research will likely explore the mechanistic aspects of TRIM63 in tumor progression, potentially unveiling new therapeutic targets.

In summary, the work from the University of Michigan reveals that the overexpression of TRIM63 gene marks a critical biomarker capable of identifying MiTF family altered renal cell carcinomas undetected by conventional FISH assays. This discovery enhances the diagnostic arsenal, offering hope for more accurate disease classification and expanded treatment modalities for patients grappling with this aggressive form of kidney cancer.

Subject of Research: Renal Cell Carcinoma, Microphthalmia-Associated Transcription Factor Family Altered RCC, TRIM63 gene expression, Diagnostic Biomarkers

Article Title: TRIM63 Overexpression in FISH-Negative MiTF Family Altered Renal Cell Carcinoma (MiTF RCC)

News Publication Date: 25-Aug-2025

Web References:
https://doi.org/10.1016/j.modpat.2025.100873
https://www.uofmhealth.org/our-care/specialty-centers-hospitals/rogel-cancer-center
https://www.pathology.med.umich.edu/
https://pubmed.ncbi.nlm.nih.gov/40865922/

References:
Mehra R., Mannan R., Chen Y-B., Wang X., Zhan Y., Hosseini N., Sangoi A.R., et al. (2025). TRIM63 Overexpression in FISH-Negative MiTF Family Altered Renal Cell Carcinoma (MiTF RCC). Modern Pathology. https://doi.org/10.1016/j.modpat.2025.100873

Keywords: Kidney cancer, Renal cell carcinoma, MiTF RCC, TRIM63, FISH assay, Gene rearrangement, Molecular diagnostics, Biomarker, Precision medicine

Traditional models used to study RCC and evaluate treatment efficacy have long suffered from significant drawbacks. Conventional two-dimensional cell cultures and animal models often fail to replicate the intricate heterogeneity and microarchitecture of human tumors, which critically influences therapy responses and disease progression. Tumors are not homogenous masses but complex ecosystems composed of varied cell populations and extracellular matrix interactions, factors that contribute to intratumoral diversity and adaptive resistance mechanisms. This complexity underlies the high variability in patient responses to chemotherapy and targeted drugs, rendering generalized treatment protocols often ineffective.

The innovative 3D bioprinting methodology developed by the Tsinghua team builds upon advances in biomaterial science, tissue engineering, and cellular biology. Utilizing patient-derived tumor cells as bioinks, the researchers were able to engineer multi-cellular constructs that incorporate endothelial-like networks, simulating the blood vessels that nourish tumors in the human body. This replication of vasculature is crucial, as it influences tumor metabolism, growth, and the delivery of therapeutic agents, factors typically absent or poorly modeled in traditional systems. These organoids thus serve as robust, physiologically relevant platforms that reflect tumor heterogeneity and microenvironmental dynamics with exceptional fidelity.

The significance of these organoids extends beyond biological fidelity; they represent a scalable and reproducible solution that mitigates labor-intensive manual methodologies predominant in current research workflows. The precise spatial control afforded by 3D bioprinting enables consistent production of tumor models, significantly expediting the process of preclinical drug screening. Researchers can now rapidly assess the efficacy of multiple therapeutic candidates in parallel, tailoring treatment strategies to the unique genetic and phenotypic profile of an individual’s tumor. This personalized approach promises to transform how nephrologists and oncologists devise treatment regimens, potentially improving clinical outcomes and reducing adverse effects associated with ineffective therapies.

Renal cell carcinoma remains a formidable clinical challenge due to its rising incidence and notorious heterogeneity. Its pathogenesis involves a multitude of genetic aberrations that evolve over time, fostering resistance to chemotherapy and targeted agents, heightening the risk of recurrence and metastasis. Conventional laboratory models struggle to capture this evolving complexity, constraining efforts to develop precision medicine protocols. By contrast, the patient-derived organoids created through this bioprinting platform faithfully preserve mutational landscapes and phenotypic traits, enabling longitudinal studies of tumor evolution and drug resistance mechanisms.

At the heart of this innovation is the meticulous integration of multidisciplinary expertise encompassing mechanical engineering, chemical system engineering, and molecular oncology. Dr. Yuan Pang, Associate Professor at Tsinghua University and co-author of this study, highlights that the ability to mass-produce heterogeneous tumor models “could greatly accelerate the discovery of effective, patient-specific treatments.” The combination of engineering precision and biological authenticity in these organoids provides an essential bridge between bench research and bedside application, epitomizing the ideals of translational medicine.

The implications of this research resonate well beyond RCC, offering a versatile framework applicable to other malignancies characterized by cellular heterogeneity and microenvironmental complexity. The capacity to bioprint organoids maintaining phenotypic fidelity opens new avenues for studying tumor-stroma interactions, immunotherapy responses, and the role of the extracellular matrix in cancer progression. Furthermore, the reduced reliance on animal testing aligns with ethical imperatives, marking progress toward more humane and efficient research methodologies.

This breakthrough also promises to influence pharmaceutical development pipelines. By enabling high-throughput screening of drug candidates on patient-specific tumor constructs, pharmaceutical companies can refine lead compounds earlier in the development process, reducing costs and attrition rates traditionally associated with oncology therapeutics. Additionally, clinicians could leverage such organoids to predict resistance patterns and adapt treatment plans dynamically, a feat previously unattainable with static biopsy samples or generic cell lines.

Moreover, the vascular-like structures incorporated into these bioprinted tumors provide a unique vantage point for studying angiogenesis—the formation of new blood vessels—a hallmark of cancer progression. Understanding how these neovessels interact with cancer cells and facilitate metastasis could inform the development of novel anti-angiogenic therapies that disrupt tumor sustenance and dissemination. This integrated modeling approach thus serves as a powerful investigative tool across multiple dimensions of tumor biology.

Despite these promising advancements, challenges remain. Scaling bioprinting techniques for routine clinical application requires further refinement to ensure reproducibility, cost-effectiveness, and regulatory compliance. Additionally, comprehensive molecular characterization of the printed organoids across diverse RCC subtypes will be essential to validate their utility broadly. Nonetheless, the current progress heralds a new era in personalized oncology research, emphasizing precision, fidelity, and translational relevance.

The study exemplifies the synergy achievable when engineering innovation meets medical necessity, charting a transformative course for kidney cancer research and therapy. As these patient-derived, bioprinted organoids become more integrated into clinical and pharmaceutical workflows, they hold the promise of enabling truly personalized medicine—where treatments are not just designed based on population averages but intricately woven around the unique biological signature of each patient’s tumor.

Subject of Research: Cells

Article Title: Bioprinting of Patient-Derived Heterogeneous Renal Cell Carcinoma Organoids for Personalized Therapy

News Publication Date: 12-Aug-2025

Web References:
https://iopscience.iop.org/article/10.1088/1758-5090/adecc5

References:
Pang, Y., Shou, J., et al. (2025). Bioprinting of Patient-Derived Heterogeneous Renal Cell Carcinoma Organoids for Personalized Therapy. Biofabrication. DOI: 10.1088/1758-5090/adecc5

Image Credits: J-VAR / IOP Publishing

Keywords: Diseases and disorders, Renal Cell Carcinoma, 3D Bioprinting, Personalized Medicine, Tumor Organoids, Cancer Research

Renal cell carcinoma remains one of the most challenging malignancies affecting the kidney, notorious for its resistance to conventional therapies and a high tendency for metastasis. The urgent search for efficacious and less toxic treatment regimens has led scientists to explore phytochemicals like berbamine, a compound derived from the traditional Chinese medicinal plant Berberis amurensis. Despite its historical use, the mechanisms by which BBM impedes RCC progression had hitherto remained obscure.

In the current study, researchers focused on two human RCC cell lines, 786-O and OSRC2, to rigorously investigate BBM’s capacity to influence cancer cell behavior. They employed a battery of functional assays to assess changes in cell proliferation, colony formation, cell cycle progression, migration, and invasive potential. These experiments were complemented by in vivo tumorigenesis models designed to evaluate BBM’s anti-tumor efficacy and systemic toxicity.

Remarkably, BBM demonstrated a robust, dose-dependent inhibition of RCC cell proliferation. The compound not only suppressed colony formation ability but also disrupted cell cycle progression, indicating a comprehensive blockade of tumor growth machinery. Functionally, BBM impaired the migratory and invasive phenotypes of the RCC cells, suggesting its potential to thwart metastatic dissemination, a leading cause of RCC mortality.

Moving beyond phenotypic observations, the study delved into molecular underpinnings, unveiling that BBM significantly augments the expression of FTO at both mRNA and protein levels. FTO, widely recognized for its role as an RNA demethylase impacting epitranscriptomic regulation, has recently garnered attention as a tumor suppressor in certain cancers. The enhancement of FTO by BBM posits a direct molecular pathway through which this natural compound exerts its anti-cancer effects.

Crucially, the authors demonstrated that silencing FTO using siRNA attenuated BBM’s inhibitory action on RCC cells’ growth and invasion. This pivotal finding establishes FTO as a necessary mediator of BBM’s anti-tumor activity, positioning the FTO pathway as an attractive target for therapeutic intervention. Such mechanistic insight underscores the potential for targeted epitranscriptomic modulation in cancer therapy.

In vivo studies further reinforced these findings, with BBM administration leading to significant suppression of tumor growth in animal models. Importantly, this was achieved without apparent toxicity to vital organs, addressing a major limitation of many chemotherapeutic agents that inflict severe systemic side effects. The favorable safety profile of BBM amplifies its promise as a candidate for clinical development.

The study’s multi-tiered approach — combining cellular assays, molecular biology techniques, and animal models — provides a robust foundation for understanding berbamine’s anti-cancer mechanisms. It also opens the door for further exploration into how FTO modulates downstream targets relevant to RCC progression and metastasis, which remain to be clarified for comprehensive therapeutic exploitation.

While berbamine’s utility in cancer has been previously hinted at, this research distinctly maps its influence within the RCC microenvironment, highlighting the integration of epitranscriptomic regulation into tumor biology frameworks. The identification of BBM as an FTO enhancer enriches the repertoire of epigenetic and epitranscriptomic modulators being investigated for cancer treatment.

The implications of these findings are especially significant in the context of metastatic RCC, where current therapeutic options are limited and often fraught with resistance. BBM’s dual capacity to inhibit proliferation and invasion addresses critical aspects of tumor aggressiveness and spread, which are paramount concerns in patient prognosis.

Moreover, the study’s revelation that FTO acts as a tumor suppressor in RCC contrasts with its oncogenic roles in other cancers, highlighting the complex, context-dependent functions of epitranscriptomic regulators. This duality underscores the necessity of precision medicine approaches tailoring therapy based on tumor-specific molecular landscapes.

Future research is warranted to characterize the direct targets of FTO in RCC cells influenced by BBM treatment. Understanding the epitranscriptomic alterations may unveil novel biomarkers for treatment response and identify combinatory strategies to enhance therapeutic efficacy.

Given berbamine’s natural origin and apparent low toxicity, translational efforts could expedite its progression into clinical trials. The prospect of integrating such a compound into RCC treatment regimens offers hope for improved outcomes through innovative, biologically inspired therapies.

In sum, this pioneering study not only delineates a novel mechanism by which berbamine hampers RCC progression by harnessing FTO expression but also enriches our conceptual framework of cancer biology, emphasizing epitranscriptomic modulation as a frontier in oncology. The therapeutic promise of BBM could catalyze a paradigm shift in combating metastatic renal cell carcinoma, fulfilling a critical unmet medical need.

Subject of Research:
The investigation focuses on the anti-tumor effects of berbamine in renal cell carcinoma cells and its molecular mechanism involving the upregulation of the fat mass and obesity-associated gene (FTO).

Article Title:
Berbamine inhibits cell proliferation and invasion by increasing FTO expression in renal cell carcinoma cells

Article References:
Xu, J., Cheng, X., Xu, M. et al. Berbamine inhibits cell proliferation and invasion by increasing FTO expression in renal cell carcinoma cells. BMC Cancer 25, 987 (2025). https://doi.org/10.1186/s12885-025-13463-y

Image Credits:
Scienmag.com

DOI:
https://doi.org/10.1186/s12885-025-13463-y

Renal cell carcinoma is the most common form of kidney cancer, notorious for its ability to invade the venous system, including the renal vein and the inferior vena cava, forming what is known as a venous tumor thrombus. This vascular infiltration complicates surgical resection and often portends a poorer outcome. Targeted therapies, such as axitinib—a potent tyrosine kinase inhibitor that disrupts vascular endothelial growth factor receptors (VEGFRs)—have emerged as promising neoadjuvant treatments, aiming to shrink the tumor thrombus before surgery. However, response rates vary widely among patients, emphasizing the urgent need to understand the biological underpinnings governing sensitivity and resistance to axitinib.

The multidisciplinary team employed an integrative approach combining transcriptomic profiling, immunohistochemistry, and advanced computational analyses on tumor samples collected pre- and post-axitinib therapy. Their goal was to identify biomarkers—particularly those related to angiogenesis and immune cell infiltration—that could reliably forecast patient responses. Through this comprehensive evaluation, the investigators discovered that the expression patterns of certain angiogenic genes, alongside the spatial arrangement and subtype composition of immune cells within both the primary tumor and the thrombus, dictate therapeutic outcomes.

One of the pivotal findings highlighted in the study is the characterization of an angiogenic signature that enshrines a finely tuned balance between pro- and anti-angiogenic factors. Patients demonstrating a predominance of pro-angiogenic signaling components, such as VEGF-A and angiopoietin-2, showed variable responsiveness to axitinib, indicating that mere upregulation of these factors is insufficient to predict efficacy. Instead, the effective inhibition of VEGFR pathways appeared contingent on the concurrent presence of specific immune modulating processes within the tumor microenvironment.

Intriguingly, the immune contexture emerged as a decisive determinant of axitinib response. Tumors exhibiting an inflamed microenvironment, characterized by an abundance of cytotoxic CD8+ T cells and antigen-presenting dendritic cells, were more likely to respond favorably to neoadjuvant treatment. Conversely, tumors with an immunosuppressive milieu, rich in regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), demonstrated resistance, pointing to the indispensable role of immune checkpoints and suppressor populations in mediating therapeutic outcomes.

The investigation further delved into the spatial heterogeneity between primary renal tumors and their associated venous thrombi. It was noted that the immune phenotypes in the thrombi were often distinct from those in the primary tumor bed, suggesting compartmentalized immune dynamics. This heterogeneity could explain the differential sensitivity sometimes observed between the primary lesion and the thrombus portion, underscoring the necessity for biopsy sampling from both sites to inform effective therapy design.

Advanced computational modeling enabled the team to integrate molecular and cellular data, generating a predictive algorithm with potential clinical utility. This model stratifies patients based on angiogenic and immune features, surmounting the limitations of conventional clinical staging and imaging. Such stratification can empower oncologists to preemptively identify those who would derive maximal benefit from axitinib neoadjuvant therapy, sparing non-responders from unnecessary toxicity and delays in definitive surgical intervention.

Moreover, the findings pave the way for combination therapies that target both angiogenesis and immune evasion mechanisms. The authors speculate that integrating immune checkpoint inhibitors alongside axitinib might synergize to overcome resistance mediated by immunosuppressive microenvironments. This concept resonates with burgeoning clinical evidence supporting combined targeted and immunotherapies in RCC, reflecting a paradigm shift toward multi-modal, precision oncology.

The implications of this study extend beyond RCC with venous thrombus, potentially influencing treatment algorithms for a variety of solid tumors exhibiting vascular invasion and reliance on angiogenic pathways. By illuminating the complex crosstalk between tumor vasculature and immune infiltrates, the work advocates for a holistic view of tumor biology that transcends singular molecular targets.

From a translational perspective, the study advocates for the integration of detailed molecular profiling into routine clinical workflows. It suggests that next-generation sequencing and immune profiling assays become indispensable tools for oncologists managing RCC patients with venous involvement. This approach aligns with the broader movement in oncology to harness biomarkers for real-time therapy adaptation, heralding an era of dynamic treatment personalization.

Importantly, this research leverages tissue samples obtained pre- and post-treatment, enabling a real-time glimpse into therapy-induced changes at molecular and cellular levels. This longitudinal insight is critical, as it reveals adaptive resistance mechanisms that could be pharmacologically targeted in subsequent treatment lines, thus sustaining therapeutic pressure on the tumor.

The study’s robust cohort design, combining clinical, pathologic, and molecular data from multiple centers, lends strong validity and reproducibility to the results. It exemplifies the power of collaborative, interdisciplinary research in tackling complex cancer challenges and delivering findings that are primed for clinical translation.

Future directions proposed by the researchers include expanding the predictive model to incorporate circulating biomarkers and imaging features, fostering non-invasive methods to monitor response dynamics. Such innovations could revolutionize surveillance strategies, enabling early detection of treatment failure and prompt therapeutic adjustments.

Furthermore, the elucidation of immune-suppressive pathways in resistant tumors invites exploration of novel agents targeting Tregs and MDSCs, potentially reversing immunosuppression and sensitizing tumors to both axitinib and immunotherapy. This angle holds promise for developing next-generation adjuvant regimens that improve survival in this high-risk RCC population.

Ultimately, this comprehensive study furnishes the oncology community with actionable insights that stand to refine neoadjuvant treatment paradigms, intensify the precision of RCC management, and inspire analogous investigations in other malignancies. The unveiling of angiogenic and immune predictors not only deepens our understanding of tumor biology in the context of vascular invasion but also empowers clinicians with tools to deliver more effective, personalized care.

As kidney cancer incidence continues to rise worldwide, innovations like these are essential to curtail morbidity and mortality. Harnessing the interplay between angiogenesis and immunity exemplifies the nuanced approach needed to conquer aggressive cancers that exploit their microenvironment for growth and dissemination.

In sum, the convergence of molecular biology, immunology, and clinical oncology represented by this work epitomizes the future of cancer therapy: integrative, predictive, and patient-centric. By leveraging biomarkers to match treatments to tumor biology, researchers and clinicians can finally close the gap between laboratory discoveries and improved patient outcomes in renal cell carcinoma complicated by venous tumor thrombus.

Subject of Research: Angiogenic and immune predictors of neoadjuvant axitinib response in renal cell carcinoma with venous tumour thrombus

Article Title: Angiogenic and immune predictors of neoadjuvant axitinib response in renal cell carcinoma with venous tumour thrombus

Article References:

Wray, R., Paverd, H., Machado, I. et al. Angiogenic and immune predictors of neoadjuvant axitinib response in renal cell carcinoma with venous tumour thrombus.
Nat Commun 16, 3870 (2025). https://doi.org/10.1038/s41467-025-58436-8

Image Credits: AI Generated